Ebola virus (EBOV) causes lethal hemorrhagic fever with case fatality rates of up to 90%. Vaccination has been key to controlling outbreaks. However, due to limited stocks of approved vaccines and stringent requirements of ultracold storage and distribution, there is a need to continue developing new vaccines with more appropriate product characteristics. Although all vaccine candidates use the surface